论文部分内容阅读
目的:比较3种方案治疗脑梗死的临床疗效并进行药物经济学成本-效果分析。方法:采用回顾性调查方法,104例脑梗死病例依据治疗方法的不同分为刺五加注射液组(Ⅰ)、脑蛋白水解物注射液组(Ⅱ)和依达拉奉注射液组(Ⅲ),运用药物经济学的成本-效果分析方法进行评价。结果:3组治疗脑梗死的成本分别为(7 467±1 643.6)元、(8408±2 784.1)元、(10 017±3 124.5)元,总有效率分别为72.97%、74.29%和93.94%,Ⅰ、Ⅱ组相对Ⅲ组患者的增量成本-效果比分别为122.71元和82.68元。结论:依达拉奉注射液治疗脑梗死较刺五加注射液和脑蛋白水解物注射液具有药物经济学优势。
OBJECTIVE: To compare the clinical efficacy of three kinds of regimens in the treatment of cerebral infarction and conduct cost-effectiveness analysis of pharmacoeconomics. Methods: According to the method of retrospective investigation, 104 cases of cerebral infarction were divided into three groups according to different treatment methods: acanthopanax senticosus injection group (Ⅰ), brain protein hydrolyzate injection group (Ⅱ) and edaravone injection group (Ⅲ) ), Using cost-effectiveness analysis of pharmacoeconomics. Results: The cost of treating cerebral infarction was (7 467 ± 1 643.6) yuan, (8408 ± 2 784.1) yuan and (10 017 ± 3 124.5) yuan in the three groups respectively, the total effective rates were 72.97%, 74.29% and 93.94% , And the incremental cost-effectiveness ratio of patients in group Ⅰ and Ⅱ relative to group Ⅲ was 122.71 yuan and 82.68 yuan respectively. Conclusion: Edaravone injection has the advantages of drug economics in the treatment of cerebral infarction compared with Acanthopanax senticosus injection and brain protein hydrolyzate injection.